Background:Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPARγ agonist. The PRESS V study was aimed to evaluate the safety, tolerability, and efficacy of saroglitazar 2 mg and 4 mg capsules (Lipaglyn™; Zydus Code: ZYH1) as compared to high dose pioglitazone in patients with diabetic dyslipidemia.Methods:In this 26-week double-blind, parallel arm, phase 3 study patients with hypertriglyceridemia with type 2 diabetes mellitus (BMI > 23 kg/m2; hypertriglyceridemia: TG > 200 to 400 mg/dL; glycosylated hemoglobin [HbA1c] >7 to 9%) were enrolled from 14 sites in India. After 2 weeks of lifestyle modification, 122 patients were randomized double-blind to 24-week treatment with the study drugs (saroglitazar 2 mg or 4 mg or pioglitazone 45 mg once daily) in a 1:1:1 ratio. The primary end point was change in plasma triglyceride level at week 24. The secondary end points were change in lipid profile and fasting plasma glucose at week 24. Patients who received study medication and had undergone at least 1 postbaseline efficacy evaluation were included in the efficacy analysis. All randomized patients who received at least a single dose were included for safety evaluation.Results:The efficacy analysis included 109 patients (n = 37 in saroglitazar 2 mg; n = 39 in saroglitazar 4 mg; n = 33 in pioglitazone). Saroglitazar 2 mg and 4 mg significantly reduced (P < .001) plasma triglyceride from baseline by 26.4% (absolute change ± SD: −78.2 ± 81.98 mg/dL) and 45% (absolute change ± SD −115.4 ± 68.11 mg/dL), respectively, as compared to pioglitazone -15.5% (absolute change ± SD: −33.3 ± 162.41 mg/dL) at week 24. Saroglitazar 4 mg treatment also demonstrated marked decrease in low-density lipoprotein (5%), very-low-density lipoprotein (45.5%), total cholesterol (7.7%), and apolipoprotein-B (10.9%). Saroglitazar treatment was generally safe and well tolerated. No serious adverse events were reported in saroglitazar treatment arm and no persistent change in laboratory parameters.Conclusions:Saroglitazar appeared to be an effective and safe therapeutic option for improving hypertriglyceridemia in patients with type 2 diabetes mellitus.

The unique herbal extract blend LI85008F, combined with modest calorie restriction and physical activity, is well tolerated, safe, and effective for weight management in overweight men and women.

We report a case of eosinophilic enteritis involving the proximal small bowel, a relatively rare entity, presenting unusually as enteroliths in a 68-year-old man with complaints of anemia, malena and abdominal pain. The disease if diagnosed in the initial stages responds well to medical treatment but if associated with complications or misdiagnosed, surgical modality is the treatment of choice. In our case, the patient presented with enteroliths and strictures. Resection and anastomosis of the small bowel containing stones was carried out. Histopathology confirmed the diagnosis as eosinophilic enteritis.

Background: According to the International Diabetes Federation “diabetes is one of the largest global health emergencies of the 21st century”. Depression and anxiety have been identified as frequent co-morbid condition in Type 2 diabetes, which is itself associated with worse outcomes including increased mortality. People with diabetes are 2 to 3 times more likely to have depression than people without diabetes. Only 25% to 50% of people with diabetes who have depression get diagnosed and treated. The diabetes anxiety depression scale (DADS) is a potentially useful instrument in screening for anxious depression in people with type 2 diabetes in clinical practice. Methods: The study was a prospective observational study done on 100 Diabetic patients in a tertiary care hospital in Bangalore during the period of 2 months from November 2022 to December 2022. Results: Among the subjects studied,57% were Male and 43% were female. The maximum number of subjects i.e., 31% were in the age group of 51-60 years. Then mean duration of Type 2 DM in the study subjects was 12.34 years. 53% were found to have poor glycaemic control which is a HbA1C value of more than equal to 8%. 31% of them scored 18-39. Score of 18-39 was suggestive of major anxious depression. Conclusions: Anxious depression was prevalent across all categories of glycemic variability. There was no statistically significant difference among glycemic variability across the anxious depression spectrum. DADS score had a positive correlation with increasing age. Male diabetic patients had more anxious depression than female patients. Female diabetic patients had poorer diabetic control over prolonged periods of time. The present study findings have potential clinical implications but also have certain limitations in terms of sample size.

No abstract